Intervenční a akutní kardiologie ve dvacátém ročníku Krátké zamyšlení nad současnou úlohou časopisů a pohled do historie

Jan František Vojáček

Interv Akut Kardiol. 2021;20(1):6-10  

Direktní stenting: ano či ne?

František Holm

Interv Akut Kardiol. 2021;20(1):11-12  

Acute decompensated heart failure at department of internal medicine: medications recommended on discharge from hospital

Marie Kalčíková, Zdeněk Monhart

Interv Akut Kardiol. 2021;20(1):13-17  

Introduction: Acute decompensated heart failure is a frequent reason for hospitalization. It is a severe diagnosis with unfavorable prognosis; however, the course of heart failure may be positively influenced by pharmacotherapy, especially by using ACEI/ARB and beta blockers. Aim: The aim is to analyze a population of patients admitted due to acute decompensation of heart failure and evaluate to what extent the medication recommended on discharge complies with the current heart failure guidelines. Material and methods: Patients admitted with the main diagnosis of I50 in 2018–2019 were observed for LVEF and the presence of...

Arrhythmias in acute and post-myocardial infarction patients

Vít Gloger

Interv Akut Kardiol. 2021;20(1):18-20 | DOI: 10.36290/kar.2021.005  

Arrhythmias are the most frequent complication of myocardial infarction. This review summarizes the up-to-date management of the most common arrhythmias in acute and post-myocardial infarction patients.

Choosing another antithrombotic therapy one year after acute coronary syndrome: why DAPT sometimes is not discontinued after 12 months

Ivo Varvařovský

Interv Akut Kardiol. 2021;20(1):23-27  

Life expectancy in the years following an acute coronary syndrome event is poor for some specific groups of patients because of their high likelihood of recurrent ischemic events. To combat this continuing risk, several clinical trials have evaluated the efficacy and safety of more intensive antithrombotic strategies - prolonged dual antiplatelet therapy (DAPT) or dual pathway inhibition approach (DPI), combining low-dose rivaroxaban and aspirin. The clinical utilization of these antithrombotic strategies requires clinicians to carefully assess the risk of recurrent ischemic and bleeding events in an individual patient.

Perspectives in the treatment of heart failure

Filip Málek

Interv Akut Kardiol. 2021;20(1):28-32  

The future of the treatment of heart failure is based on methods aimed at slowing or reversing the progressive course of the disease. In patients in a less advanced stage of heart failure, the research is focused on the modulation of autonomic regulation and cardiac remodeling in HFrEF. New interventional methods are also tested in patients with HFpEF.

Sudden cardiac arrest requiring cardiopulmonary resuscitation during downhill skiing

Lucia Masárová, Jiří Seménka, Roman Panovský, Lukáš Opatřil

Interv Akut Kardiol. 2021;20(1):33-36 | DOI: 10.36290/kar.2021.006  

Despite advances in pharmacological and non-pharmacological treatment, cardiovascular diseases are a major cause of morbidity and mortality in developed countries. This case report introduces a case of a 41-year-old female patient who suffered a sudden cardiac arrest during skiing, which required cardiopulmonary resuscitation. Pulmonary embolism, aortic dissection, and cerebral hemorrhage were excluded by performing a computed tomography scan. Subsequently, a critical finding was observed on coronary angiography, necessitating a triple aortocoronary bypass surgery with good effect. In the next phase, familial hypercholesterolemia was diagnosed and...

TAVI u nízkorizikových pacientů TAVI in low-risk patients

Marian Branny

Interv Akut Kardiol. 2021;20(1):51-55  

The COLCOT trial

Lenka Špinarová, Jindřich Špinar, Jiří Vítovec

Interv Akut Kardiol. 2021;20(1):44-45  

The COLCOT trial evaluated the administration of colchicine versus placebo in patients after myocardial infarction. The trial was conducted based on a clinical hypothesis that inflammatory processes may play a role in the process of atherogenesis and its complications. The primary composite endpoint was: time to cardiovascular death, cardiac arrest, myocardial infarction, stroke, urgent hospitalization for angina pectoris leading to revascularization. A primary endpoint event occurred in 5.5 % of the patients in the colchicine group as compared with 7.1 % of those in the placebo group (p < 0.02). The overall mortality did not differ between the...

Results of the VICTORIA trial: Vericiguat in patients with heart failure with reduced ejection fraction

Vojtěch Melenovský

Interv Akut Kardiol. 2021;20(1):46-48  

The report summarizes the results of the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial which tested vericiguat, a soluble guanylate cyclase (sGC) stimulator, in the treatment of patients with heart failure and reduced left ventricular ejection fraction who had recently been hospitalized. This agent significantly reduced the primary endpoint (hospitalization for heart failure or cardiovascular death) by 10 % and has recently been approved by the FDA.

Evaluation of pulmonary vein anatomical variants in patients with atrial fibrillation

Barbora Farkasová, David Pospíšil, Tomáš Novotný, Monika Míková, Ondřej Toman, Milan Sepši, Petr Kala

Interv Akut Kardiol. 2021;20(1):37-43 | DOI: 10.36290/kar.2021.002  

This review summarizes and compares the methods and results of available original papers on the evaluation of anatomical variants of pulmonary veins in patients with atrial fibrillation published in the last two decades. The studies included show that an understanding of anatomical variants of pulmonary veins is an important prerequisite for successful catheter ablation of atrial fibrillation. The present text deals with an analysis and mutual comparison of the methods and results used in various evaluations of the original authors.

Tony Gershlick, a British pioneering coronary interventionist and a friend of Czech interventional cardiology, passed away

Jan Kovac

Interv Akut Kardiol. 2021;20(1):56  

In memory of Jiří Kolář, MD

Jan František Vojáček

Interv Akut Kardiol. 2021;20(1):57-58 | DOI: 10.36290/kar.2021.019